Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of ABT-888 (veliparib) and SCH727965 (dinaciclib)
in patients with advanced solid tumors.

II. To determine the recommended phase 2 dose (RP2D) for ABT-888 in combination with
SCH727965, determined by evaluating the feasibility, safety, dose-limiting toxicities, and
the maximally tolerated dose(s).

SECONDARY OBJECTIVES:

I. To confirm the safety of the combination of ABT-888 and SCH727965 in patients with known
BRCA1 or BRCA2 germline mutation.

II. To characterize the pharmacokinetic parameters of ABT-888 both alone and in combination
with SCH727965.

III. To assess the pharmacodynamic effects of ABT-888 in combination with SCH727965, both in
surrogate tissues and in tumor.

IV. To assess preliminary antitumor activity of the ABT-888/SCH727965 combinations in
subjects with solid tumors.

OUTLINE: This is a dose-escalation study of veliparib and dinaciclib followed by expanded
doublet cohort studies of non-breast BRCA-proficient patients and BRCA-proficient triple
negative breast cancer (TNBC) patients, a safety doublet cohort for BRCA-deficient patients,
and cohorts of BRCA-associated TNBC (PARP inhibitor-naive and PARP inhibitor-resistant).

PART 1A: Patients receive veliparib orally (PO) twice daily (BID) on days 1-28 and dinaciclib
intravenously (IV) over 2 hours on days 8 and 22. Cycles repeat every 28 days in the absence
of disease progression or unacceptable toxicity.

PART 1B: Patients receive veliparib and dinaciclib as patients in Part 1A. Cycles repeat
every 28 days in the absence of disease progression or unacceptable toxicity.

PART 1C: Patients receive veliparib PO BID on days 1-7 of course 0. Patients then receive
veliparib PO BID on days 1-21 and dinaciclib IV over 2 hours on days 1, 4, 8, and 11 or days
1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable
toxicity.

After completion of study treatment, patients are followed up every 3 months.

Inclusion Criteria:

- Participants must have histologically confirmed diagnosis of a solid tumor for which
no curative therapy exists

- Participants must have measurable or evaluable disease

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2

- Prior chemotherapy is allowed; patients must not have received chemotherapy for 3
weeks prior to the initiation of study treatment and must have full recovery from any
acute effects of any prior chemotherapy; patients must not have had nitrosoureas or
mitomycin C for 6 weeks prior to the initiation of study treatment

- Prior exposure to approved receptor tyrosine kinase inhibitors is permitted; at least
5 half-lives must have elapsed since the completion of the kinase inhibitor and the
initiation of study treatment

- Prior radiation therapy is allowed; patients must not have received any radiation
within 3 weeks prior to the initiation of study treatment; patients may not have areas
of irradiated marrow exceeding 40% of bone marrow volume

- Prior experimental (non-Food and Drug Administration [FDA] approved) therapies and
immunotherapies are allowed; patients must not have received these therapies for 3
weeks prior to the initiation of study treatment and must have full recovery from any
acute effects of these therapies

- Prior exposure to ABT888 or other PARP inhibitors is permitted in all cohorts; prior
exposure to cyclin-dependent kinase inhibitors other than SCH727965 is permitted

- Absolute neutrophil count >= 1,500/mm^3

- Hemoglobin (Hgb) > 10.0 g/dL with no blood transfusion in the past 28 days

- Platelets >= 100,000/mm^3

- Total bilirubin < 1.5 mg/dl

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 times the institutional upper limit of normal; for subjects with known liver
metastases, AST and ALT =< 5 times institutional upper limit of normal

- Creatinine =< 1.5 times institutional upper limit of normal or creatinine clearance >=
60 mL/min/1.73 m^2

- Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin
time (PTT) =< 1.5 times institutional upper limit of normal

- The effects of ABT-888 and SCH727965 on the developing human fetus are unknown; for
this reason, women of childbearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to study
entry and for the duration of study participation; should a woman become pregnant or
suspect she is pregnant while participating in this study, she should inform her
treating physician immediately; additionally, if a man suspects that he has fathered a
child while taking study agents, he should also inform his treating physician
immediately

- Eligible patients in the dose escalation phases of the trial must agree to biopsies of
normal skin, unless they undergo optional tumor biopsies; the mandatory biopsy
requirement can be waived at the discretion of principal investigator in the event of
any medical contraindication (e.g. lidocaine allergy); patients enrolled to the
expanded cohorts must agree to tumor sampling; patients on anticoagulation must be
able to hold warfarin or low molecular weight heparin for a sufficient amount of time
to make skin and tumor biopsies safe to perform; PT/INR and PTT should be =< 1.5 times
the institutional upper limit of normal prior to performance of skin or tumor
biopsies, with values re-checked after the eligibility screen as medically indicated

- Patients must be able to swallow pills

- Patients enrolling in the BRCA-deficient cohorts must have a documented BRCA1 or BRCA2
germline mutation; alternatively, patients with tumors harboring somatic BRCA
mutations may also enroll after discussion with the principal investigator

- All patients must agree to provide an archival tissue block or paraffin sample from
archival tissue block (approximately 10 sections) for use in pharmacodynamic
correlative studies; however, patients are not considered ineligible if archival tumor
is not available

- Ability to understand and the willingness to sign a written informed consent document;
subjects must be willing to adhere to dose and visit schedules

Exclusion Criteria:

- Patients must not receive any other anti-cancer therapy (cytotoxic, biologic,
radiation, or hormonal other than for replacement) while on this study except for
medications that are prescribed for supportive care but may potentially have an
anti-cancer effect (i.e. megestrol acetate, bisphosphonates); in addition, men
receiving treatment for prostate cancer will be maintained at castrate levels of
testosterone by continuation of luteinizing-releasing hormone agonists; palliative
radiation therapy (XRT) can be administered on study after documented discussion with
the principal investigator; for patients in expansion cohorts, this must not involve
target lesions

- Patients with known active brain metastases are excluded; patients with a history of
central nervous system (CNS) metastases that have been treated must be stable with no
symptoms for > 3 months after completion of that treatment and off steroid treatment,
with image documentation required prior to study enrollment

- Any patient requiring chronic maintenance of white blood cell counts or granulocyte
counts through the use of growth factor support (e.g. Neulasta, Neupogen)

- Patients who have previously received SCH727965

- Patients with other medical conditions judged by the investigator to be clinically
relevant in the setting of this study, which may include active infectious processes,
intractable emesis, or chronic diarrheal disease

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, or
psychiatric illness/social situations that would limit compliance with study
requirements

- Pregnant women are excluded from this study because ABT-888 and SCH727965 are
anti-proliferative agents with the potential for teratogenic or abortifacient effects;
because there is an unknown but potential risk of adverse events in nursing infants
secondary to treatment of the mother with ABT-888 and SCH727965, breastfeeding should
be discontinued if the mother is treated with ABT-888 and SCH727965; these potential
risks may also apply to other agents used in this study

- Patients with prior seizure history who have experienced a seizure within the three
months prior to enrollment are excluded

- Subjects with a known allergy to lidocaine

- Subjects on a potent CYP3A4 inhibitor or CPY3A4 inducer who cannot be changed to
another medication are excluded

- Subjects with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic
syndrome (MDS) or with features suggestive of AML/MDS

- Prior allogeneic bone marrow transplant or double umbilical cord blood transplantation